Tianyin Pharmaceutical has formed a joint venture with Sichuan Mingxin Pharmaceutical Co. to produce macrolide antibiotics, such as azithromycin, clarithromycin and roxithromycin. Tianyin will own 77% of the JV, which will be known as Sichuan Jiangchuan Pharmaceutical Co., Ltd. Although Tianyin was historically focused on TCM products, it received its first SFDA approval for an antibiotic, Azithromycin Dispersible Tablets, in 2008. More details...

Stock Symbol: (NYSE Alternext: TPI)